MedTrace Logo

Study of Challenge Meditech 082 (CM082) Tablets in Patients With Advanced Malignant Solid Tumors

NCT03792958 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2022-11-14

No results posted yet for this study

Summary

This is a Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Oral Dosing of CM082 tablets in Chinese Patients With Advanced Malignant Solid Tumors

Conditions

  • Advanced Malignant Solid Tumors

Interventions

DRUG

CM082

CM082 tablets taken orally 200、400、600 and 800 mg (QD or BID)

Sponsors & Collaborators

  • Shanghai East Hospital

    collaborator OTHER

  • AnewPharma

    lead INDUSTRY

Principal Investigators

  • Jin Li, M.D · Shanghai East Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-26
Primary Completion
2023-06-30
Completion
2023-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03792958 on ClinicalTrials.gov